Biomecite’s IBD Diagnostic Tool to Be Evaluated in Proof of Concept Study

Biomecite’s IBD Diagnostic Tool to Be Evaluated in Proof of Concept Study
Biomecite Diagnostics, LLC, a medical diagnostics company, recently announced that it is enrolling patients for a proof of concept study whose goal is to assess the accuracy of a new diagnostic technology for inflammatory bowel disease (IBD). Biomecite’s IBD diagnostic tool is based on a microbiome signature technology developed at the University of Maryland, Baltimore. It explores the differences in the microbiome (bacterial population) found in the human gut in order to determine whether patients suffering from gastrointestinal problems have IBD, and also allows the discrimination between two IBD types, ulcerative colitis and Crohn’s disease. This proof of concept study is being performed in collaboration with the CSSi Life Sciences in Glen Bur
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *